Hillstream BioPharma is a development stage company focused on rare cancers.  By harnessing a weakness in tumors to preferentially concentrate Hillstream’s proprietary Quatramer^TM technology, we are developing targeted cancer therapies.  The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory cytokines directly into the tumor’s genome.  We will work to improve the lives of patients as we rapidly move into the clinic to treat small cell lung cancer, soft-tissue sarcomas and other high unmet need rare cancers.